Weaver, Amy

INTRODUCTION: Rates of long acting reversible contraception (LARC) use, including LNGIUS and LD-LNGIUS the United States are increasing. The aim of this study was to compare rates of and reasons for discontinuation of these two LARC. METHODS: Following IRB approval, premenopausal women 13-55 years old undergoing LD-LNGIUS (13.5 mg) insertion for contraception at Mayo Clinic Rochester from 1/1/2013 to 12/31/2015 were identified (n=82). A random sample of 328 women meeting the same criteria with LNGIUS insertion was identified. The cumulative incidence of discontinuation for symptom-related complaints was compared between groups after taking into account discontinuation for other reasons as a competing risk. RESULTS: Compared to those with LNGIUS, women with LD-LNGIUS were younger (mean age, 25.9 vs. 30.3 years), more likely to be nulliparous (86.6% vs. 28.0%), less likely to have previously used LARC (13.4% vs. 35.1%), and had lower BMI (mean, 25.2 vs. 27.0 kg/m 2 ). In women with subsequent follow-up, 57.3% (43/75) of the women with LD-LNGIUS expressed a symptom concern compared to 60.9% (171/281) of the women with LNGIUS. The cumulative incidence of discontinuation for symptom-related complaints by 2 years was higher in the LD-LNGIUS group, with rates of 20.0% vs. 13.8% based on patients with follow-up and 23.4% vs.12.8% based on a subset of 58+58 women matched on age, race, gravidity, and insertion year. CONCLUSION: Women with LD-LNGIUS are less likely to express symptom concerns than women with LNGIUS, but more likely to discontinue for symptom-related complaints. These findings may inform counseling of women with hormonal intrauterine contraception placement.